Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has entered into a definitive agreement to acquire the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of $600m.
Subscribe to our email newsletter
The agreement will strengthen AstraZeneca’s aclidinium respiratory franchise and is expected to add immediate revenues with long-term growth potential.
Upon completion of the transaction, AstraZeneca will own the development and commercial rights to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD.
As part of the deal, AstraZeneca will also own development rights for LAS40464, the combination of a fixed dose of aclidinium with formoterol long acting beta agonist (LAMA/LABA) in a dry powder inhaler.
Currently, LAS40464 is approved in the European Union (EU) under the brand name Duaklir Genuair.
In 2014, Tudorza Pressair and Daliresp had combined annual sales in the US of about $230m.
AstraZeneca US president and AstraZeneca North America executive vice-president Paul Hudson said: "Our agreement with Actavis builds on our acquisition of Almirall’s respiratory portfolio and brings long-term value to one of our key growth platforms.
"With the addition of Tudorza and Daliresp, we will benefit from an immediate boost to revenue in our biggest market, further strengthening our growing respiratory franchise.
"This combined portfolio helps us to offer an even broader range of innovative treatments and formulations to physicians and pulmonary specialists for patients suffering with COPD."
Additionally, AstraZeneca will also pay $100m to Actavis, which has agreed to a number of contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between the two firms.